𝔖 Bobbio Scriptorium
✦   LIBER   ✦

BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING AGENT IN TREATMENT OF PARKINSON'S DISEASE

✍ Scribed by Agid, Y.; Bonnet, A.M.; Pollak, P.; Signoret, J.L.; Lhermitte, F.

Book ID
122066767
Publisher
The Lancet
Year
1979
Tongue
English
Weight
385 KB
Volume
313
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adjuvant treatment of parkinson's diseas
Adjuvant treatment of parkinson's disease with dopamine agonists: Open trial with bromocriptine and CU 32-085
✍ Kurt Jellinger πŸ“‚ Article πŸ“… 1982 πŸ› Springer 🌐 English βš– 820 KB

Bromocriptine (CB-154) and the 8-alpha-ergoline CU 32-085, two dopamine receptor agonists, were administered at different times to two series of 22 patients with Parkinson's disease, most of whom took levodopa (plus benserazide) at optimum dosage. The addition of bromocriptine (mean daily dose 32 mg

Association of a polymorphism in the dop
Association of a polymorphism in the dopamine-transporter gene with parkinson's disease
✍ Dr. David G. le Couteur; Peter W. Leighton; Sally J. McCann; Susan M. Pond πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 341 KB πŸ‘ 1 views

## Abstract The presynaptic dopamine transporter in nigral dopaminergic neurons confers susceptibility to the cytotoxic effects of the neurotoxic metabolite of 1‐methy1‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Polymorphisms in the dopamine transporter might influence the susceptibility to such toxins.